Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals concluded the fourth quarter of 2025 with $2.67 billion in cash and equivalents, reflecting an increase from $2.24 billion at the end of the third quarter, indicating strong financial positioning. The company anticipates that revenue growth will surpass operating expense increases, bolstered by significant quarterly revenue growth in the familial chylomicronemia syndrome (FCS) launch, which saw a 56% increase driven by strong demand from specialists. Furthermore, positive developments in ongoing clinical trials and potential milestones associated with upcoming product launches are likely to enhance revenue prospects, supporting a favorable long-term outlook for Ionis Pharmaceuticals.

Ionis Pharmaceuticals faces a negative outlook due to anticipated revenue declines in 2026, primarily resulting from a shift in pricing strategies as it launches Tryngolza for a much larger indication while navigating a crowded market for HAE treatments. The company has reported significant financial losses, with projections indicating a non-GAAP operating loss of $500-550 million, which falls short of consensus estimates. Additionally, Ionis's projected revenue guidance of $800-825 million for 2026 is also below analyst expectations of $914 million, suggesting ongoing challenges in achieving profitability and raising concerns about potential future dilution.